Gamma Biosciences, a global life sciences company serving the academic and advanced therapy market, has appointed Dale Gordon as Chief Executive Officer (CEO) of its operating company Mirus Bio.
Gordon succeeds founders Jon Wolff and Jim Hagstrom in carrying the scientific legacy of the company forward with an expanded focus on enabling both the research and biopharmaceutical manufacturing markets.
The company has been delivering transfection reagents to the research community for more than two decades and is now moving into biopharma with the introduction of TransIT-VirusGEN GMP transfection reagents, enhancers and kits earlier this year. The product line offers users the ability to package and transfer vector DNA to suspension and adherent HEK 293 cell types for increased production of recombinant AAV and lentivirus, while helping to minimize safety and regulatory risks.
Gordon brings more than three decades of global leadership experience in life sciences to the new role, most recently as CEO of Gemini Biosciences. Prior to Gemini, Gordon held commercial leadership roles at GE Life Sciences (now Cytiva) and Merck Millipore.